Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared on LinkedIn about a recent article by Berkan Kurt et al, published in European Heart Journal:
”Many myths and misconceptions persist regarding the use of the biomarker of inflammation C-reactive protein measured with a highly sensitive assay (hsCRP)
Serial measurements are as stable as cholesterol or blood pressure.
The independent association with future events, independent of traditional risk factors, has been replicated multiple times.
This report of an analysis of almost half a million participants in the UK Biobank should help lay to rest some the concerns commonly voiced about this potent predictor of cardiovascular risk.
Although not causal in cardiovascular events, this excellent analyte can select individuals who can benefit from therapies including statins (JUPITER) and anti-inflammatory interventions (CANTOS)”
Title: C-reactive protein and cardiovascular risk in the general population
Authors: Berkan Kurt , Martin Reugels , Kai M Schneider , Jens Spiesshoefer , Andrea Milzi , Alexander Gombert , Christopher B Fordyce , Florian A Wenzl , Neha J Pagidipati , Viviane Rocha , Marat Fudim , Abhinav Sharma , Michael Lehrke , Hiroaki Shimokawa , Giovanna Liuzzo , Lale Tokgozoglu , Filippo Crea , Thomas F Lüscher , Peter Libby , Paul M Ridker , Nikolaus Marx , Carolin V Schneider , Florian Kahles
Read the Full Article on European Heart Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation